Roy S. Herbst, MD, PhD; Vincent A. Miller, MD; and Alan B. Sandler, MD, present and discuss 3 case studies highlighting the factors that go into making challenging non-small-lung cancer treatment decisions, with particular consideration of biomarker analysis, use of adjuvant therapy, and maintenance therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare and contrast treatment options for patients with advanced non-small-cell lung cancer in terms of choice of agent or modality, timing, and sequence
- Describe the role of maintenance therapy in patients with advanced non-small-cell lung cancer
- Summarize the use of platinum-doublet chemotherapy with or without a targeted agent in the treatment of non-small-cell lung cancer
- Interpret the results of recent clinical studies of tyrosine kinase inhibitors as adjuvant therapy in patients with resected non-small-cell lung cancer who have EGFR mutations
- Describe the role of adjuvant therapy for patients with resectable non-small-cell lung cancer
Abstract